Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ontogeny Inc.

Division of Curis Inc.

Latest From Ontogeny Inc.

Ontogeny Grows the Family Tree

The merger of Creative BioMolecules, Ontogeny, and Reprogenesis to form Curis Inc. was designed to build value long-term. Driven by their common focus on regenerative medicine, Curis combines near-term and longer-term product opportunities and creates a more formidable discovery engine to compete with larger companies in the field.
BioPharmaceutical Business Strategies

When the Body Alone Can't Build Bone

Orthobiologics are now on the horizon, driving suppliers to increase R&D spending. The goal is to develop high-margin products that will actively promote bone formation. Has the slow progress to commercialization of the first two products--bone morphogenic proteins developed by the collaborations of Stryker Corp/Creative Biomolecules and Genetics Institute/Sofamor Danek--helped prime the market to accept a new technology? Or has the perception of delay dampened enthusiasm and scared off some of the big orthopedics players?
BioPharmaceutical Medical Device

Becton Dickinson Votes for Biology

Becton Dickinson, with huge shares in its core markets, has turned increasingly to research-intensive, high-payoff projects for its future growth. Its most ambitious program is in genetic diagnostics, where recent deals with The Institute for Genomic Research and Millennium Predictive Medicine have made it the diagnostics industry's highest-flying dealmaker. Its hope is to find the rarest and most valuable of all diagnostic products: a patented disease marker.
BioPharmaceutical Medical Device

Delving into Developmental Biology

Industry experts agree companies have little choice but to engage in developmental biology research, if they're aiming for drugs to treat the causes, not just the symptoms, of disease.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Parent & Subsidiaries
  • Curis Inc.
  • Senior Management
  • Contact Info
  • Ontogeny Inc.
    ,
Advertisement
Advertisement
UsernamePublicRestriction

Register